Omakase Lab 3 2018 – Burden of Cancer in Spain

//Omakase Lab 3 2018 – Burden of Cancer in Spain

Omakase Lab 3 2018 – Burden of Cancer in Spain

Omakase, with the collaboration of Bristol Myers-Squibb, has released the third volume of Omakase’s Lab report series: “The Burden of Cancer in Spain”.

In this report, Omakase has analysed the impact of cancer in Spain for the year 2015 by analysing its epidemiological burden, formed by the prevalence at 5 years (cancer cases), the incidence (new cases of cancer), mortality and inability; and its economic burden, consisting of direct costs (costs of using SNS resources), indirect costs (costs of productivity loss) and intangible costs (years of healthy life lost due to cancer).

2018-10-09T08:58:18+00:00September 20th, 2018|Omakase thought leadership Lab|

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our cookies policy, Click on the link for more information. ACEPTAR

Aviso de cookies